Altered Contractile Response due to Increased β3-Adrenoceptor Stimulation in Diabetic Cardiomyopathy

The Role of Nitric Oxide Synthase 1–derived Nitric Oxide

Julien Amour, M.D., Ph.D.,* Xavier Loyer, B.Sc.,† Morgan Le Guen, M.D.,* Nejma Mabrouk, M.D.,* Jean-Stéphane David, M.D., Ph.D.,‡ Emmanuel Camors, Ph.D.,§ Nunzia Carusio, B.Sc.,∥ Benoît Vivien, M.D., Ph.D.,* Ramaroson Andriantsihofaina, Ph.D.,# Christophe Heymes, Ph.D.,** Bruno Riou, M.D., Ph.D.††

Background: In the diabetic heart, the positive inotropic response to β-adrenoceptor stimulation is altered and β1 and β2 adrenoceptors are down-regulated, whereas β3 adrenoceptor is up-regulated. In heart failure, β3-adrenoceptor stimulation induces a negative inotropic effect that results from endothelial nitric oxide synthase (NOS)-derived nitric oxide production. The objective of our study was to investigate the role of β3 adrenoceptor in diabetic cardiomyopathy.

Methods: β3-Adrenergic responses were investigated in vivo (dobutamine echocardiography) and in vitro (left ventricular papillary muscle) in healthy and streptozotocin-induced diabetic rats. The effect of β3-adrenoceptor inhibition on the inotropic response was studied in vitro. Immunoblots and NOS activities were performed in heart homogenates (electron paramagnetic resonance) and isolated cardiomyocytes. Data are mean percentage of baseline ± SD.

Results: The impaired positive inotropic effect was confirmed in diabetes both in vivo (121 ± 15% vs. 160 ± 16%; P < 0.05) and in vitro (112 ± 5% vs. 179 ± 15%; P < 0.05). In healthy rat, the positive inotropic effect was not significantly modified in presence of β3-adrenoceptor antagonist (17 ± 20%), nonselective NOS inhibitor (N^3-nitro-l-arginine methyl ester [l-NNAME]; 183 ± 19%), or selective NOS1 inhibitor (vinyl-l-N-(5-1-imino-3-butenyl)-l-ornithine [l-VNIO]; 172 ± 13%). In diabetes, in parallel with the increase in β3-adrenoceptor protein expression, the positive inotropic effect was partially restored by β3-adrenoceptor antagonist (137 ± 8% vs 105% P < 0.05), l-NNAME (133 ± 11% P < 0.05), or l-VNIO (130 ± 13%; P < 0.05). Nitric oxide was exclusively produced by NOS1 within diabetic cardiomyocytes. NOS2 and NOS3 proteins were undetectable.

Conclusions: β3-Adrenoceptor is involved in altered positive inotropic response to β3-adrenoceptor stimulation in diabetic cardiomyopathy. This effect is mediated by NOS1-derived nitric oxide in diabetic cardiomyocyte.

* Assistant Professor, Department of Anesthesiology and Critical Care, Centre Hospitalier Universitaire (CHU) Pitié-Salpêtrière. † Biological Sciences Student, INSERM U689. ‡ Staff Anesthesiologist, Department of Anesthesiology and Critical Care, CHU Edouard Herriot. § Research Assistant, INSERM U689. ¶ Biological Sciences Student, UMR-INSERM 771–CRNS 6214. ** Research Director, UMR-INSERM 771–CRNS 6214. *** Research Director, INSERM U689. †† Professor of Anesthesiology and Critical Care, Head of the Laboratory of Anesthesiology (EA 3975), Chairman, Department of Emergency Medicine and Surgery, CHU Pitié-Salpêtrière.

Received from the Université Pierre et Marie Curie-Paris 6, Laboratoire d’Anesthesie-Réanimation (EA 3975), Département d’Anesthesie-Réanimation, CHU Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France; INSERM U689, CHU Lariboisière, Université Denis Diderot-Paris 7, Paris, France; Département d’Anesthesie-Réanimation, CHU Edouard Herriot, Hospices Civils de Lyon, Lyon, France; UMR-INSERM 771–CRNS 6214, CHU d’Angers, Université d’Angers, Angers, France; Service d’Accueil des Urgences, and CHU Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Université Pierre et Marie Curie-Paris 6, Paris, France. Submitted for publication February 20, 2007. Accepted for publication May 24, 2007. Dr. Mabrouk was the recipient of a research fellowship grant from the Fondation pour la Recherche Médicale, Paris, France. This work was also supported by the Institut National de la Santé et de la Recherche Médicale (Paris, France) and grants from INSERM (Programme National de Recherche sur les Maladies Cardiovasculaires), the Association Française contre les Myopathies (Paris, France), and the Fondation de France (Paris, France) (to Dr. Heymes). Mr. Loyer was recipient of a Ministère de la Recherche et de la Technologie and a grant from Société Française d’Hypertension Artérielle/Merk-Schuchardt (Msd)-Chabret. Other support was provided from institutional and/or departmental sources.

Address correspondence to Dr. Amour: Département d’Anesthesie-Réanimation, CHU Pitié-Salpêtrière, 47-83 Boulevard de l’Hôpital, 75065 Paris cedex 13, France. julien.amour@psl.aphp.fr. Information on purchasing reprints may be found at www.anesthesiology.org or on the masthead page at the beginning of this issue. Anesthesiology’s articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue.

Anesthesiology. V 107, No 3, Sep 2007 452

Copyright © by the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.
The plasma fraction was collected and stored at +4°C. Up-regulation of nNOS participated, and to determine the NOS isoform involvement. The blood glucose level was determined to ensure that the rats became diabetic (Glucotrend; Boehringer, Manheim, Germany) was performed to confirm diabetes. The rats were given water ad libitum and were given rat chow and water ad libitum. Diabetes mellitus was induced using streptozotocin (65 mg/kg; Sigma Chemical, L’Isle d’Abeau Chesnes, France), which was injected intraperitoneally. Animals were divided into two groups, a healthy group and a diabetic group. Diabetes was confirmed 1 week later, as previously reported. All animals had access to rat chow and water ad libitum and were given rat chow and water ad libitum. The study was performed under the supervision of authorized researchers in authorized laboratories in accordance with the regulations issued by the French Ministry of Agriculture.

Materials and Methods

Care of the animals used conformed to the published Guiding Principles in the Care and Use of Animals, and the study was performed under the supervision of authorized researchers in authorized laboratories in accordance with the regulations issued by the French Ministry of Agriculture.

Animals

Six-week-old male Wistar rats (Charles River, Saint Germain sur l’Arbresle, France) were divided into two groups, a healthy group and a diabetic group. Diabetes mellitus was induced using streptozotocin (65 mg/kg; Sigma Chemical, L’Isle d’Abeau Chesnes, France), which was injected intraperitoneally. Six-week-old male Wistar rats (Charles River, Saint Germain sur l’Arbresle, France) were divided into two groups, a healthy group and a diabetic group. Diabetes mellitus was induced using streptozotocin (65 mg/kg; Sigma Chemical, L’Isle d’Abeau Chesnes, France), which was injected intraperitoneally. The rats were studied 4 weeks later, as previously reported. All animals had access to rat chow and water ad libitum. Transcutaneous determination of blood glucose level (Glucotrend; Boehringer, Manheim, Germany) was performed to ensure that the rats became diabetic (i.e., a blood glucose level > 35 mm). At the moment of euthanasia, blood samples were withdrawn from diabetic and control rats and were centrifuged at 5,000 g for 15 min. The plasma fraction was collected and stored at +4°C for further determination of glucose and bicarbonate concentration (Cobas Integra 400; Roche Diagnostik, Manheim, Germany).

Transsthoracic Echocardiography

Echocardiography was performed on anesthetized rats (1–2% isoflurane) using a General Electric Vivid 7 instrument (Aulnay-sous-Bois, France) equipped with an 8- to 14-MHz linear transducer. Data were transferred online to a computer for analysis (EchoPAC PC version 2.0.x; General Electric, Velzy, Paris). Left ventricular diameter was measured in the parasternal long-axis and short-axis views in M mode. Left ventricular ejection fraction, using a modified version of Simpson’s monoplane analysis, and left ventricular shortening fractions were measured. Left ventricular diastolic parameters were derived from pulsed-wave spectral Doppler mitral inflow (peak velocity of early E, late filling waves A, isovolumic relaxation time) and from pulsed-wave spectral mitral tissue Doppler imaging from apical view (peak early diastolic velocity, Ea), with the sample volume paced at the lateral corner of the mitral annulus as reported previously. The E/A ratio was used to evaluate the diastolic function associated the E/Ea ratio, which is used to measure the left ventricular end-diastolic pressure independently of load conditions. Dobutamine (4 μg/kg) was administrated intraperitoneally, and measurements were performed when the increase in heart rate was stabilized.

Isolated Left Ventricular Papillary Muscle

After brief anesthesia with pentobarbital sodium, the heart was quickly removed. The whole heart and the left ventricular were dissected and weighed, and the left ventricular papillary muscles were carefully excised and suspended vertically in a 200-ml jacketed reservoir with Krebs-Henseleit bicarbonate buffer solution (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.1 mM KH2PO4, 25 mM NaHCO3, 2.5 mM CaCl2, and 4.5 mM glucose) and maintained at 29°C with a thermostatic water circulator. Preparations were field stimulated at 12 pulses/min with 5-ms rectangular wave pulses set just above threshold. The bathing solution was bubbled with 95% O2 and 5% CO2, resulting in a pH of 7.40. After a 60-min stabilization period with the initial muscle length at the apex of length–active isometric tension curve (Lmax), papillary muscles recovered their optimal mechanical performance. The extracellular concentration of Ca2+ was decreased from 2.5 mM to 0.5 mM because rat myocardial contractility is nearly maximal at 2.5 mM. Conventional mechanical parameters at Lmax were calculated from three twitches. The first twitch was isometric and was loaded with the preload corresponding to Lmax. The second twitch was abruptly clamped to zero load just after the electrical stimulus with a critical damping. The third twitch was fully isometric at Lmax. We determined the maximum unloaded shortening velocity (Vmax) using the zero-load technique and time to peak shortening of the twitch with preload only. In addition, the maximum isometric active force normalized per cross-sectional area and the time to peak force were recorded from the isometric twitch. At the end of the study, the muscle cross-sectional area was calculated from the length and weight of papillary muscle, assuming a density of 1.

Anesthesiology, V 107, No 3, Sep 2007
β-Adrenoceptor stimulation was induced with cumulative concentrations of isoproterenol (10^-8 to 10^-4 M), a nonselective β-adrenoceptor agonist, in the presence of phenolamine (10^-5 M).

To assess the role of the β1 adrenoceptor, we studied additional groups exposed to S-cyanopindolol hemifumurate salt (10^-12 M), a β1-adrenoceptor antagonist previously studied in the rat,^28^ or to N^G^-nitro-l-arginine methyl ester (l-NAME; 10^-5 M), an unspecific NOS inhibitor, or to vinlyl-N^5^-cyano-l-arginine methyl ester (l-NAME; 10^-4 M), a specific NOS1 inhibitor. The combination of S-cyanopindolol and l-NAME was also tested. We studied additional experimental groups exposed to forskolin (5 x 10^-5 M), which directly activates adenyl cyclase, or dibutyryl cyclic adenosine monophosphate (dB-cAMP; 5 x 10^-4 M), a fat-soluble and diffusible analog of cyclic adenosine monophosphate resistant to hydrolysis in the intracellular involvement, as previously reported. The total volume of added drugs did not exceed 2% of the bath volume. All drugs were purchased from Sigma Chemical (L’Isle d’Abeau Chesne, France), except l-NAME, which was purchased from Coger (Paris, France).

**Isolated Cardiomyocyte**

Single ventricular cardiomyocytes were enzymatically (1 mg/ml collagenase, Worthington type II) isolated from 10-week-old control or diabetic rats (n = 5 per group), as previously described. Isolated cells were then snap-frozen and used for NOS activity assay and Western blot experiments.

**NOS Activity, Immunoblotting, and Coimmunoprecipitation Assays**

The nitric oxide content was first assayed on left ventricular homogenates, as described previously after formation of the paramagnetic adduct, Fe(II)nitrilotetraacetate (dithyldithiocarbamate [DETC])_2, detectable by electron paramagnetic resonance spectrometry in samples treated (for 30 min at 37°C) with 0.5 mM Fe(II)(DETC)_2 complex as colloid. Tissues were frozen in liquid nitrogen until electron paramagnetic resonance spectrometry measurements. Electron paramagnetic resonance spectrometry spectra were recorded on an MS100 spectrometer (Magnetech GmbH, Berlin, Germany) under the following conditions: temperature, 77°C K; microwave frequency, 9.34 GHz; microwave power, 20 mW; modulation frequency, 100 kHz; modulation amplitude, 0.5 mT; and time constant, 100 ms. After electron paramagnetic resonance spectrometry measurements, the tissue samples were dried and weighted. The relative (II) nitric oxide (DETC)_2 concentrations (A/W_d.w) were determined dividing the third component amplitude (A) of the three-electron electron paramagnetic resonance spectrometry signal by the weight of the dried sample (W_d.w).

Nitric oxide synthase activity was also measured on isolated cardiac myocytes by the conversion of (^3H)-L-arginine to (^3H)-L-citrulline, using a commercial kit (nitric oxide synthase assay kit; Calbiochem, Darmstadt, Germany). Assays for specific NOS1 and NOS2 activities were performed in the presence of l-VNIO (10^-3 M) and specific NOS2 inhibitor (1,400 W, 0.1 μM).

Western blots and coimmunoprecipitation were performed with specific antibodies to measure protein expression of β1 and β3 adrenoceptors, NOS1, NOS2, and caveolin 3. Because the most of the positive inotropic effect of β-adrenergic stimulation results from the β1 adrenoceptor, whereas β2 adrenoceptor had an insignificant role in positive inotropic effect in the diabetic cardiomyopathy, Western blots were performed especially to quantify the β1 and β3 adrenoceptor protein expression. Cardiomyocytes were homogenized in Triton X-100 buffer (1% Triton X-100 with 50 mM Tris-HCl pH 7.4, 100 mM NaCl, 50 mM NaF, 5 mM EDTA, 40 mM β-glycerophosphate, 0.2 mM orthovanadate, 0.1 mM leupeptin, and 0.001 mM aprotinin) for 1 h at 4°C. After centrifuging at 15,000 g for 15 min at 4°C, supernatant protein concentrations were measured using the BCA protein assay kit (Pierce, Perbio Sciences, Brebières, France). For β-adrenoceptors, proteins were prepared, as previously described. Fifty micrograms protein per lane was immunoblotted using rabbit polyclonal antibody against NOS1 (1:500, Affinity Bioreagents, Saint Quentin en Yvelines, France), anti-NOS2 (1:1,000, Transduction Laboratories, San Jose, CA), anti-β1 adrenoceptor (1:1,000; Affinity Bioreagents), and goat polyclonal anti-β3 adrenoceptor (1:1,000; Santa Cruz Biotechnology, Le Perray en Yvelines, France). All the Western blot experiments were quantified using normalization including a standardization of the different gels by loading a reference sample on every gel and checking that a similar total amount of protein was loaded by measurement of total protein level present on the membrane colored by S-Ponceau. The S-Ponceau staining enabled us to verify that equal amounts of protein were loaded. Accordingly, all the results were normalized with a link (actin) and the amounts of protein transferred on the membrane, and the relation between NOS1 and NOS3 was based on these corrected values. A control by performing a Western blot using a housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase, was performed and validated that there was no variation on protein gel loading in our hands.

For coimmunoprecipitation assays, cardiomyocytes lysates (150 μg protein) were incubated overnight at 4°C with either a monoclonal antibody for Cav-3, polyclonal antibody for NOS3 or NOX1 (Santa Cruz Biotechnology) at a final concentration of 4 μg/ml in 200 μl intraperitoneal buffer (1% Triton X-100, and 100 mM NaCl, 10 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.2 mM orthovanadate, and 0.2 mM PMSF). Immune complexes
were precipitated for an additional 3 h by the addition of anti-mouse immunoglobulin G–conjugated agarose (50 μl) or protein A–conjugated agarose (15 μl), centrifuged, washed three times, and then boiled in Laemmli loading buffer. Samples were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotted with a monoclonal antibody for NOS3 or NOS1 (1:1,000; Santa Cruz Biotechnology), a monoclonal antibody for caveolin 3 (1:1,000; Transduction Laboratories), respectively.

**Statistical Analysis**

Data are expressed as mean ± SD. Comparison of two means was performed using the Student t test or Mann-Whitney test for non-gaussian distribution of the variables. Comparison of several means was performed using one-way analysis of variance and Newman-Keuls test. All P values were two-tailed, and a P value less than 0.05 was considered significant. Statistical analysis was performed using NCSS 2001 software (Statistical Solutions Ltd., Cork, Ireland). Concentration–response curves were determined by fitting the data to the Hill equations according to the following equation:

\[ \text{Eff}_o = \text{Eff}_{\text{max}} \cdot (1 + (C_{50} \cdot C^{-1})^n)^{-1}, \]

in which \( \text{Eff}_o \) is the observed effect, \( \text{Eff}_{\text{max}} \) is the maximum effect, \( C_{50} \) is the concentration that results in 50% of \( \text{Eff}_{\text{max}} \), and \( C \) is the studied concentration and \( n \) the Hill coefficient. Iterative nonlinear regression curve fitting was used to obtain the best fit (Matlab 1.2c software; The MathWorks, South Natick, MA).

**Results**

We studied 52 healthy and 64 diabetic rats. No data were missing for the analyses in this study. Diabetic rats had significantly lower body weight (218 ± 31 vs. 348 ± 43 g; \( P < 0.05 \)) and heart weight (472 ± 75 vs. 715 ± 76 mg; \( P < 0.05 \)) than healthy rats, without significant difference in the heart weight to body weight ratio (2.2 ± 0.2 vs. 2.1 ± 0.2 mg/g; not significant [NS]). Blood glucose levels were four times higher in diabetic rats than in healthy rats (45 ± 6 vs. 10 ± 1 mm; \( P < 0.05 \)). Serum bicarbonate levels were slightly higher in diabetic rats (25 ± 4 vs. 24 ± 4 mm; \( P < 0.05 \)), showing that ketoacidosis did not occur.

**Contractile Responses to β-Adrenergic Stimulation**

Using echocardiography, we measured in vivo the baseline characteristics in healthy and diabetic rats. Systemic function was preserved in diabetic rats as shown by the normal values of ejection fraction (92 ± 4% vs. 89 ± 3%; \( P < 0.05 \)) and shortening fraction (58 ± 7% vs. 55 ± 4%; NS). The heart rate was not significantly different between healthy and diabetic rats (338 ± 36% vs. 318 ± 26%, respectively; NS). In contrast, diastolic function was altered in the diabetic group as shown by the prolongation of isovolumic relaxation time (29 ± 8 vs. 22 ± 1 ms; \( P < 0.05 \)) and the increased value E/A (2.6 ± 0.9 vs. 1.3 ± 0.2; \( P < 0.05 \)). Left ventricular end-diastolic pressure was increased as shown by the E/Es ratio (16 ± 4 vs. 12 ± 3; \( P < 0.05 \)). These results were confirmed in vitro using 56 left ventricular papillary muscles from healthy rats and 64 from diabetic rats. Maximum unloaded shortening velocity was significantly decreased in diabetic rats (2.73 ± 0.36 vs. 3.24 ± 0.33 Lmax/s; \( P < 0.05 \)), whereas active force was not (64 ± 28 vs. 62 ± 18 mM/mm²; NS). Prolongation of the duration of contraction was observed in diabetic rats as shown by the prolongation of time to peak shortening (212 ± 24 vs. 173 ± 13 ms; \( P < 0.05 \)) and time to peak force (186 ± 25 vs. 149 ± 16 ms; \( P < 0.05 \)).

β-Adrenoceptor stimulation induced a marked positive inotropic effect in healthy rats both in vivo (table 1) and in vitro (table 2 and fig. 1). This positive inotropic effect was markedly diminished in diabetic rats in vivo (table 1) and in vitro (table 2 and fig. 1).

**Table 1. Inotropic Response to β-Adrenoceptor Stimulation (4 μg/kg Dobutamine) in Healthy and Diabetic Rats In Vivo Using Echocardiography**

<table>
<thead>
<tr>
<th></th>
<th>Healthy Rats (n = 10)</th>
<th>Diabetic Rats (n = 8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate, % baseline value</td>
<td>109 ± 6*</td>
<td>105 ± 7*</td>
</tr>
<tr>
<td>Ejection fraction, % baseline value</td>
<td>112 ± 3*</td>
<td>104 ± 1†</td>
</tr>
<tr>
<td>Shortening fraction, % baseline value</td>
<td>160 ± 16*</td>
<td>121 ± 15†</td>
</tr>
</tbody>
</table>

Values are mean ± SD. * \( P < 0.05 \) vs. baseline value. † \( P < 0.05 \) vs. healthy rats.

\(-\text{NAME per se} did not significantly modify active force in healthy (100 ± 5% of baseline; NS) and diabetic (100 ± 5% of baseline; NS) rats in the presence of the \( \beta_1 \)-adrenoceptor antagonist \( S^{-}\text{cyanopindolol} \), the positive inotropic effect of \( \beta \)-adrenoceptor stimulation was not significantly modified in healthy rats. In contrast, \( S^{-}\text{cyanopindolol} \) partially restored the positive inotropic effect of \( \beta \)-adrenoceptor stimulation in diabetic rats (table 2 and fig. 1).

\( l^{-}\text{NAME per se} did not significantly modify active force in healthy (100 ± 5% of baseline; NS) and diabetic (100 ± 5% of baseline; NS) rats. In the presence of \( l^{-}\text{NAME} \), a nonselective NOS inhibitor, the positive inotropic effect of \( \beta \)-adrenoceptor stimulation was not significantly modified in healthy rats. In contrast, \( l^{-}\text{NAME} \) partially restored the positive inotropic effect of \( \beta \)-adrenoceptor stimulation in diabetic rats (table 2 and fig. 1). No further improvement was observed with the association of \( S^{-}\text{cyanopindolol} \) and \( l^{-}\text{NAME} \) (table 2).

\( l^{-}\text{VNIO per se} did not significantly modify isometric active force normalized per cross-sectional area in healthy (100 ± 1% of baseline; NS) and diabetic (100%...
In healthy rats (or of dB-cAMP (83% of the mean response in healthy rats). Finally, S-cyanopindolol and L-NAME markedly restored the positive inotropic of β-adrenoceptor stimulation in diabetic rats as compared with healthy rats. Data are mean percentage of baseline value ± SD (n = 8 in each group).

Expression of β-Adrenoceptor Subtypes

In agreement with the functional changes observed in the papillary muscle experiments, we found that the abundance of protein for β₁- adrenoceptor was reduced by 33% in diabetic hearts compared with levels measured in healthy hearts (fig. 4). In contrast, compared with levels observed in healthy hearts, β₁- adrenoceptors were significantly increased in diabetic hearts (fig. 4).

Potential Role of NOS-increased Nitric Oxide Production in β₂-Adrenoceptor Effect

In failing heart, previous studies have demonstrated that the contractile effect of β₂- adrenoceptor agonist is not significantly modify the positive inotropic effect of forskolin in diabetic rats (fig. 3).

Table 2. Effects of S-Cyanopindolol, L-NAME, and Both S-Cyanopindolol and L-NAME and L-VNIO on the Inotropic Responses to β-Adrenoceptor Stimulation (Isoproterenol) in Healthy and Diabetic Rats (n = 8 Papillary Muscles in Each Group)**

<table>
<thead>
<tr>
<th></th>
<th>Healthy Rats</th>
<th></th>
<th>Diabetic Rats</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>V&lt;sub&gt;max&lt;/sub&gt;</td>
<td>AF</td>
<td></td>
<td>V&lt;sub&gt;max&lt;/sub&gt;</td>
</tr>
<tr>
<td><strong>Eff&lt;sub&gt;max&lt;/sub&gt;, %</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>182 ± 11*</td>
<td>179 ± 15*</td>
<td>128 ± 7†</td>
<td>112 ± 5†</td>
</tr>
<tr>
<td>S-cyanopindolol</td>
<td>178 ± 7*</td>
<td>174 ± 20*</td>
<td>161 ± 12††</td>
<td>137 ± 8††</td>
</tr>
<tr>
<td>L-NAME</td>
<td>183 ± 10*</td>
<td>183 ± 19*</td>
<td>166 ± 12††</td>
<td>133 ± 11††</td>
</tr>
<tr>
<td>S-cyanopindolol and L-NAME</td>
<td>189 ± 18*</td>
<td>181 ± 21*</td>
<td>156 ± 15††</td>
<td>133 ± 13††</td>
</tr>
<tr>
<td>L-VNIO</td>
<td>185 ± 12*</td>
<td>172 ± 13*</td>
<td>158 ± 19††</td>
<td>130 ± 13††</td>
</tr>
<tr>
<td><strong>C&lt;sub&gt;SD&lt;/sub&gt;, μM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.11 ± 0.06</td>
<td>0.16 ± 0.12</td>
<td>0.07 ± 0.06</td>
<td>0.07 ± 0.05</td>
</tr>
<tr>
<td>S-cyanopindolol</td>
<td>0.08 ± 0.08</td>
<td>0.10 ± 0.07</td>
<td>0.14 ± 0.11</td>
<td>0.29 ± 0.26</td>
</tr>
<tr>
<td>L-NAME</td>
<td>0.07 ± 0.09</td>
<td>0.08 ± 0.11</td>
<td>0.16 ± 0.11†</td>
<td>0.45 ± 0.83</td>
</tr>
<tr>
<td>S-cyanopindolol and L-NAME</td>
<td>0.07 ± 0.04</td>
<td>0.14 ± 0.08</td>
<td>0.06 ± 0.05</td>
<td>0.11 ± 0.12</td>
</tr>
<tr>
<td>L-VNIO</td>
<td>0.10 ± 0.09</td>
<td>0.42 ± 0.26</td>
<td>0.09 ± 0.06</td>
<td>0.10 ± 0.14</td>
</tr>
</tbody>
</table>

Values are mean ± SD.

* P < 0.05 vs. baseline value. † P < 0.05 vs. healthy rats. ‡ P < 0.05 vs. control group.

AF = active force per cross-sectional area; C<sub>SD</sub> = concentration of isoproterenol that results in 50% of Eff<sub>max</sub>; Eff<sub>max</sub> = maximum effect in percentage of baseline value; L-NAME = N<sup>α</sup>-nitro-L-arginine methylester; L-VNIO = vinyl-L-N-5-(1-imino-3-butenyl)-L-ornithine; V<sub>max</sub> = maximum unloaded shortening velocity.

± 2% of baseline; (NS) rats. In the presence of L-VNIO, a selective NOS1 inhibitor, the positive inotropic effect of β-adrenoceptor stimulation was not significantly modified in healthy rats. In contrast, L-VNIO partially restored the positive inotropic effect of β-adrenoceptor stimulation in diabetic rats (table 2 and fig. 1).

Figure 2 shows the comparison of the stimulation of β-adrenoceptors by isoproterenol, the stimulation of adenyl cyclase by forskolin, or direct stimulation by dB-cAMP. The magnitude of restoration of active force obtained with S-cyanopindolol (78 ± 10% of the mean response in healthy rats) was not significantly different from those of forskolin (76 ± 16% of the mean response in healthy rats) or of dB-cAMP (83 ± 18% of the mean response in healthy rats). Finally, S-cyanopindolol did not significantly modify the positive inotropic effect of forskolin in diabetic rats (fig. 3).
mediated, at least in part, through a stimulation of NOS3-induced nitric oxide production within the cardiomyocytes. To determine the potential relation between $\beta_3$-adrenoceptor negative inotropic effect and nitric oxide, we first determined nitric oxide production in total left ventricular homogenates, using Fe-DETC electron paramagnetic resonance spectrometry (Magnettech GmbH). We observed that total nitric oxide production was not only significantly increased in diabetic rat hearts (fig. 5), but also that, using specific NOS isoform inhibitors, the main sources for the increase in cardiac nitric oxide production in left ventricular homogenates, containing endothelial cells, were NOS2 and NOS1.

In additional experiments, to assess more specifically the NOS isoform involved in this increased nitric oxide production within the cardiomyocyte exclusively, we performed both Western blot and coimmunoprecipitation on isolated cardiomyocytes from healthy and diabetic rat hearts. We were unable to detect any signal for NOS2 protein expression in either group (fig. 5). NOS3 protein expression was significantly decreased in diabetic homogenate hearts (fig. 5). To determine the potential role of cardiomyocyte NOS1-derived nitric oxide in $\beta_3$-adrenoceptor functional effect, NOS1 and NOS3 were immunoprecipitated with anti–caveolin-3 antibody (figs. 5 and 6). Although immunoblotting with monoclonal anti–caveolin-3 antibody revealed one band in the supernatant, no signal for NOS3 protein was immunoprecipitated in cardiomyocytes extracted from both groups. The same results were obtained when caveolin 3 was immunoprecipitated with polyclonal anti-NOS3 antibody. In contrast, Western blot analyses confirmed significantly greater expression of NOS1 protein in diabetic than in healthy cardiomyocytes homogenates (fig. 6). Immunoblotting with monoclonal anti–caveolin-3 antibody revealed interaction between NOS1 and caveolin 3 in cardiomyocytes extracts both in

![Fig. 3. Effect of S-cyanopindolol (10^{-12} M) on the positive inotropic effects of isoproterenol (10^{-4} M) and forskolin (5 \times 10^{-5} M) in left ventricular papillary muscles from diabetic rats, under high load. AF = isometric active force normalized per cross-sectional area; NS = not significant. Data are mean percentage of baseline value ± SD (n = 8 in each group). * P < 0.05 versus control diabetic group.](image)

![Fig. 4. Representative Western blot and densitometric data reflecting $\beta_1$-adrenoceptor (A) and $\beta_3$-adrenoceptor (B) expression in healthy and diabetic heart samples. Results are expressed as mean ± SD. * P < 0.05 versus healthy group.](image)

![Fig. 5. (A) Net nitric oxide (NO) levels in left ventricle homogenates from healthy and diabetic rats using Fe(diethylthiocarbamate [DETC]) electron paramagnetic resonance (n = 6 in each group). l-VNIO = vinyl-l-N-5-(1-imino-3-butenyl)-l-ornithine. (B) Representative Western blot for NO synthase (NOS) 2 in isolated cardiomyocytes from healthy and diabetic rats. C+ corresponds to positive controls. (C) Representative Western blot for NOS3 left ventricle homogenates from healthy and diabetic rats. (D) Coimmunoprecipitation NOS3/Cav-3 from cardiomyocyte extracts of healthy and diabetic rats. IP = Immunoprecipitate; S. = supernatant fraction. * P < 0.05 versus healthy group.](image)
Nide production in diabetic cardiomyocyte was attribut-
was down-regulated. Moreover, the increased nitric ox-
in diabetic rats. 13,15,18–20 We observed that this
vitro
tor antagonist, a nonselective NOS inhibitor, or a selec-

tive NOS1 inhibitor in diabetic heart and confirmed that
been difficult to demonstrate a significant difference as
compared with the nearly undetectable positive inotro-
pic effect noted in diabetic cardiomyopathy. To test the
hypothesis of
adrenoceptor stimulation, we have
able to the NOS1 activity. These results suggest that β3
adrenoceptor plays an important role in the β-adrenergic
dysfunction associated with diabetic cardiomyopathy
and that this effect is exclusively mediated by NOS1-
derived nitric oxide.

As reported previously, we observed important alter-
ations in the myocardium of diabetic rats using left
ventricular papillary muscles.7,14,18–20 In particular, we
noted a decrease in Vmax without change in active force,
which was associated with a marked prolongation of the
contraction phase. The decrease in Vmax has been asso-
ciated with an isomyosin shift from V1 (αα dimer) to V3
(ββ dimer).35 whereas the prolongation of contraction
has been related to a slower cross-bridge cycling rate, a
slower Ca2+ release from the sarcoplasmic reticulum,
and an alteration of Ito potassium current.36 Using echo-
cardiography, we confirmed in vitro the diastolic dys-
function usually described in diabetic cardiomyopathy
in vivo
by the prolongation of isovolumic relaxation time
and the increase in E/A and E/Ea, which is independent
of loading conditions.37 Systolic function was still un-
changed at this relatively short time of disease evolution
(4 weeks of diabetes) in accordance with unchanged
active force in papillary muscles.

The role of β3 adrenoceptor seems well established
both in healthy and failing hearts.15–17,38–40 In this spe-
cific context, it has been shown that stimulation of β3
adrenoceptors results in NOS3-derived nitric oxide
which is at the beginning of cyclic guanosine monophos-
phate production.16,38–41 Thereafter, cyclic guanosine
monophosphate activates inhibitory G proteins, which
decrease the dB-cAMP production resulting from β1-
adrenoceptor stimulation and thus induces a negative
inotropic effect.15,16,39,41 In our study, we confirmed the
predominance of β1-adrenoceptor protein expression in
comparison with the β3-adrenoceptor protein in healthy
heart.

Using left papillary muscles, the positive inotropic ef-
fect of β-adrenoceptor stimulation was not significantly
enhanced by the β3-adrenoceptor antagonist administra-
tion as previously reported.42

In diabetes, using dobutamine echocardiography, we
confirmed in vivo the impaired positive inotropic effect
of β-adrenoceptor stimulation previously reported in left
ventricular papillary muscles.18 We also confirmed the
overexpression of β3-adrenoceptor protein and the
down-regulation of β1-adrenoceptor protein, in accor-
dance with a previous study.22 Because of the collapsed
positive inotropic effect of the β-adrenergic stimulation,
we have chosen to use a β3-adrenoceptor antagonist able
to restore part of the positive inotropic effect rather than
an agonist of β3 adrenoceptor because it would have
been difficult to demonstrate a significant difference as
compared with the nearly undetectable positive inotro-
pic effect noted in diabetic cardiomyopathy. To test the
hypothesis of β3-adrenoceptor involvement, we have

Discussion

In the current study, we confirmed in vivo and in vitro
the markedly decreased positive inotropic effect of
β-adrenoceptor stimulation as previously reported in
vitro
in diabetic rats.13,15,18–20 We observed that this
effect was partially restored using a direct β3-adrenoce-
tor antagonist, a nonselective NOS inhibitor, or a selec-
tive NOS1 inhibitor in diabetic heart and confirmed that
β3 adrenoceptor was up-regulated and β1 adrenoceptor
was down-regulated. Moreover, the increased nitric ox-
ide production in diabetic cardiomyocyte was attribut-

Fig. 6. (A) Representative Western blot for nitric oxide synthase (NOS) 1 in isolated cardiomyocytes from healthy and diabetic rats. (B) Immunoprecipitation NOS1/Cav-3 from cardiomyo-
ocyte extracts of healthy and diabetic rats. IP = immunoprecipi-
tate; S = supernatant fraction. (C) Bar graphs displaying total activity using Nω-nitro-l-arginine methyl ester (l-NAME; nonse-
lective NOS inhibitor) and percentage NOS activity inhibited by
vinyl-l-N-5-(1-imino-3-butenyl)-l-ornithine (l-VNIO; NOS1 in-
hibitor) in isolated cardiomyocytes from healthy and diabetic
rats. Results are expressed as mean ± SD (n = 5 in each group).
* P < 0.05 versus healthy group.

healthy and in diabetic rats (fig. 6). To confirm the above
results, we determined the specific activity of NOS1 in
the same preparation of isolated cardiomyocytes by the
conversion of (3H)-l-arginine to ( 3H)-l-citrulline, using
the specific NOS1 inhibitor l-VNIO. With l-VNIO (10−4
m), more than 90% of total cardiomyocyte calcium-dep-
dendent NOS activity was found to be attributable to
NOS1 in diabetic rats (fig. 6).

Discussion

In the current study, we confirmed in vivo and in vitro
the markedly decreased positive inotropic effect of
β-adrenoceptor stimulation as previously reported in
vitro
in diabetic rats.13,15,18–20 We observed that this
effect was partially restored using a direct β3-adrenoce-
tor antagonist, a nonselective NOS inhibitor, or a selec-
tive NOS1 inhibitor in diabetic heart and confirmed that
β3 adrenoceptor was up-regulated and β1 adrenoceptor
was down-regulated. Moreover, the increased nitric ox-
id production in diabetic cardiomyocyte was attribut-

Downloaded From: http://anesthesiology.pubs.asahq.org/pdfaccess.ashx?url=/data/journals/jasa/931057/ on 11/01/2018
used S-cyanopindolol, a specific antagonist of the β3 adrenoceptor in rat. The positive inotropic effect of β-adrenoceptor stimulation was partially restored by S-cyanopindolol in diabetic left ventricular papillary muscle. In addition, the administration of L-NAME to inhibit nitric oxide produced by the stimulation of β3-adrenoceptor was also able to restore the positive inotropic effect of β-adrenoceptor stimulation in diabetic rats in accordance with studies performed in heart failure.17 The effects of S-cyanopindolol and L-NAME were comparable, and no further improvement was noted with their association. The magnitude of the maximum restoration induced by inhibition of β3 adrenoceptor could have been underestimated because we used a very low concentration of S-cyanopindolol. Nevertheless, it should be pointed out that higher concentrations could also partly antagonize β3 adrenoceptors because specificity is likely to be at least partly lost at high concentrations, as we observed in a preliminary study (data not shown). However, the fact that the association of S-cyanopindolol and L-NAME was not superior to each drug alone suggests that the correction reached its maximum. A complete restoration with β3-adrenoceptor inhibition was not expected because diabetic cardiomyopathy results from a variety of alterations not only related to the adrenoceptor signaling pathway. In fact, through the direct activation of adenyl cyclase by forskolin or the direct exposure to db-cAMP, we observed that these alterations were also partly responsible for the decreased responses in diabetic rats. Our results suggest that most of the alterations responsible for the impairment in the β adrenoceptors and situated upward adenyl cyclase activity are linked to β3 adrenoceptor. Indeed, the residual impairment after inhibition of β3 adrenoceptors was comparable to that observed with forskolin or db-cAMP.

In the current study, we observed that in diabetes, as in heart failure,17,38 β3 adrenoceptor plays an important role in the impairment of the inotropic response to β-adrenoceptor stimulation. In heart failure, previous studies have suggested that β3-adrenoceptor agonists increase nitric oxide production either through direct activation of a constitutively expressed NOS, most likely NOS3. NOS2 and NOS3 were thought to be the sole isoform responsible for increased nitric oxide production within the cardiomyocyte of the failing heart.17,38,41 More recently, identification of the NOS1 isoform in cardiomyocytes has markedly improved the understanding of the critical role of NOS1-derived nitric oxide in the control of myocardial contractility both in the normal and the failing heart. NOS1 has been found to be associated with the cardiac ryanodine receptor Ca2+ release channel in the cardiac sarcoplasmic reticulum, suggesting that cardiac NOS1-derived nitric oxide may modulate ion channels/transporters involved in myocardial Ca2+ cycling and contraction.29 In diabetic cardiomyopathy, for the first time and in accordance with our previous results regarding the role of NOS1-induced nitric oxide production in heart failure,29,43,44 we have demonstrated that NOS1 protein expression was predominant and that nitric oxide production resulted quasi-exclusively from NOS1 within the isolated diabetic cardiomyocytes. The NOS3 isoform protein expression was found in homogenate heart of diabetic rats, probably within endothelial cells, but was not in the cardiomyocyte. NOS2 protein expression was undetectable in the same preparations. Our data support the idea that cardiac NOS1-derived nitric oxide is involved in the autocrine regulation of β-adrenergic (β1- and β3-adrenoceptor subtypes) contractile responses in diabetic cardiomyopathy and may explain, in part, the increased perioperative cardiovascular lability and the more frequent perioperative need of vasoactive agents observed in diabetic patients.45 Therefore, these findings suggest that part of the collapsed response to the β-adrenergic stimulation could be corrected by the antagonism of the β3-adrenoceptor pathway and could at least partly restore cardiac output by the inotropic effect induced.

The following points should be considered when assessing the clinical relevance of our results. First, this study was performed in rat myocardium, which differs from human myocardium. Second, streptozotocin induces diabetes of type I, which is not the most frequently encountered clinical form. Nevertheless, streptozotocin-induced diabetic rat is widely used and is recognized as an appropriate animal model of diabetes, most of myocardial dysfunction being present after 4 weeks without any streptozotocin toxicity. Third, because L-NAME and L-VNIO restored, in part, the positive inotropic effect of β-adrenergic stimulation, we have chosen to use a specific antagonist of β3 adrenoceptor more than a specific agonist to compare their respective capacity to restore the positive inotropic effect. Whether a specific agonist of β3 adrenoceptor could be used, comparison between positive and negative inotropic magnitudes was less relevant. Fourth, a part of this study was performed during anesthetic agent exposure, which is susceptible to interfere with the β-adrenergic stimulation in diabetes as previously reported.18,46 Last, the effects of insulin therapy were not studied. However, although insulin therapy may restore the diastolic dysfunction at the beginning of the disease,22 apoptosis and fibrosis rapidly occur in diabetic heart,47 and therefore, insulin therapy may not be sufficient to reverse all abnormalities involved in diabetic cardiomyopathy.

In conclusion, we observed that the β3 adrenoceptor plays an important role in the β-adrenergic dysfunction associated with diabetic cardiomyopathy and that β3 adrenoceptor effect is mediated by NOS1-derived nitric oxide. The development of new therapeutic strategies based on these findings might be interesting for the treatment of shock or hemodynamic instability in diabetic patients.
References


